Clavis Pharma raises $27 million
This article was originally published in Scrip
Oslo-listed Clavis Pharma has closed a private placement to raise NOK163 million ($27 million). The money will give it greater flexibility in negotiating out-licensing deals, envisaged in 2013, and to consider new cancer product opportunities, it said. The firm has two advanced-stage oncology products, elacytarabine and CP-4126, for which key data is expected over the next year or so.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.